GSK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

8.42B

+3.76%

0.608

+4.9%

7.81B

+3.92%

1.200

-0.3%

8.28B

+3.64%

1.271

+2.45%

Estimates Revision

The market is revising No Change the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 22.05%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+22.05%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 48.880

Low

45.00

Averages

45.00

High

45.00

Current: 48.880

Low

45.00

Averages

45.00

High

45.00

HSBC

Rajesh Kumar

Reduce

maintain

2025-12-10

Reason

HSBC

Rajesh Kumar

Price Target

2025-12-10

maintain

Reduce

Reason

HSBC analyst Rajesh Kumar raised the firm's price target on GSK to 1,500 GBp from 1,200 GBp and keeps a Reduce rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Mizuho

Graig Suvannavejh

Outperform

maintain

2025-12-09

Reason

Mizuho

Graig Suvannavejh

Price Target

2025-12-09

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh keeps an Outperform rating on Ideaya Biosciences (IDYA) after the company disclosed the termination of its partnership with GSK (GSK) for two early-stage pipeline programs. The partnership termination, which Ideaya said reflects GSK moving away from synthetic lethality, is "both a surprise and of course, a disappointment," the analyst tells investors in a research note. However, Mizuho says both programs are early-stage and are not included in its model. The removal of future anticipated milestone payments from GSK has no significant impact on Ideaya's financial prospects, it adds.

JPMorgan

Underweight -> NULL

upgrade

2025-12-08

Reason

JPMorgan

Price Target

2025-12-08

upgrade

Underweight -> NULL

Reason

JPMorgan raised the firm's price target on GSK to 1,700 GBp from 1,500 GBp and keeps an Underweight rating on the shares.

Berenberg

Kerry Holford

Hold

maintain

2025-11-26

Reason

Berenberg

Kerry Holford

Price Target

2025-11-26

maintain

Hold

Reason

Berenberg analyst Kerry Holford raised the firm's price target on GSK to 1,660 GBp from 1,600 GBp and keeps a Hold rating on the shares.

BofA

Underperform -> Neutral

upgrade

2025-11-25

Reason

BofA

Price Target

2025-11-25

upgrade

Underperform -> Neutral

Reason

BofA upgraded GSK to Neutral from Underperform with a price target of 2,000 GBp, up from 1,700 GBp. GSK has a busy and "contentious" FY26 with two launches - Blenrep and Depemokimab - and three key pipeline events, the analyst tells investors. These events all help shape a "narrative of growth" in the specialty business potentially being sufficient to offset the HIV patent cliff, the analyst added.

Stifel

Hold

Buy

upgrade

$16 -> $40

2025-11-10

Reason

Stifel

Price Target

$16 -> $40

2025-11-10

upgrade

Hold

Buy

Reason

Stifel upgraded Cogent Biosciences (COGT) to Buy from Hold with a price target of $40, up from $16, after the company reported "overwhelmingly positive" results in the Phase 3 PEAK study of bezuclastinib plus sunitinib versus sunitinib alone in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors. The combination arm PFS of 16.5 months is significantly higher than investor expectations of 11-12 months and this result also helps ward off competitive pressure from (GSK) GSK, which at CTOS reported a Phase 1 PFS of 15 months in second-line GIST, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 10.95, compared to its 5-year average forward P/E of 10.02. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

10.02

Current PE

10.95

Overvalued PE

13.85

Undervalued PE

6.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

8.12

Current EV/EBITDA

7.49

Overvalued EV/EBITDA

9.96

Undervalued EV/EBITDA

6.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.07

Current PS

2.17

Overvalued PS

2.42

Undervalued PS

1.72

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GSK News & Events

Events Timeline

No data

News

9.0

12-13NASDAQ.COM

FDA Grants Approval for Johnson & Johnson's AKEEGA to Treat BRCA2-Mutated Prostate Cancer

9.0

12-12Benzinga

FDA Considers Black Box Warning for COVID Vaccines Amid Expert Opposition

9.0

12-12SeekingAlpha

GSK Receives EU Approval to Sell Arexvy RSV Vaccine for All Adults

People Also Watch

Frequently Asked Questions

What is GSK plc (GSK) stock price today?

The current price of GSK is 48.88 USD — it has decreased -0.73 % in the last trading day.

What is GSK plc (GSK)'s business?

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

What is the price predicton of GSK Stock?

What is GSK plc (GSK)'s revenue for the last quarter?

GSK plc revenue for the last quarter amounts to 11.52B USD, increased 10.62 % YoY.

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

GSK plc. EPS for the last quarter amounts to 0.66 USD, decreased -3400.00 % YoY.

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

How many employees does GSK plc (GSK). have?

GSK plc (GSK) has 68629 emplpoyees as of December 16 2025.

What is GSK plc (GSK) market cap?

Today GSK has the market capitalization of 99.31B USD.